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In the cell nucleus, DNA is wound around histone proteins, which are then packed together to form chromatin. Histones can be 
chemically tagged by methyl and acetyl groups. Polycomb group (PcG) proteins attach methyl groups to genes, which block their 
activity. This is similar to the attachment of methyl groups to gene promoters by DNA methyltransferases (DNMTs). This action 
is directly linked with tumor initiation and metastasis via the promotion of anti-senescence and anti-apoptosis pathways, and by 
facilitating epithelial mesenchymal transition (EMT). Cell fate transcriptional factors (CFTFs) and long non-coding RNAs (long 
ncRNAs) recruit PcG proteins to the promoters of tumor suppressor genes, resulting in epigenetic gene silencing by influencing 
chromatin structure and DNA accessibility. Thus, PcG proteins are potential diagnostic markers and targets for new chemopre-
vention and therapeutic strategies. 
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Tumorigenesis has traditionally been considered to be driv-
en by the sequential acquisition of mutations, leading to the 
activation of oncogenes and to the loss of function of tumor 
suppressor genes. An increasingly large amount of evidence 
suggests that carcinogenesis also involves “epigenetic 
changes”, which are mediated by mechanisms that do not 
affect the primary DNA sequence. Epigenetic changes in-
clude both genome-wide loss and regional gain of DNA 
methylation, and aberrant post-translation modifications of 
histones. Both DNA methylation and histone modification 
have key functions in governing gene expression by influ-
encing chromatin structure and DNA accessibility. Abnor-
mal chromatin structure can cause inappropriate gene ex-
pression and genomic instability, which results in cellular 
transformation and malignant growth. Therefore, proteins 
that control chromatin structure are important in carcino-
genesis. Polycomb group proteins (PcG proteins), which 
regulate chromatin remodeling, are one such class of pro-
teins that regulate chromatin structure. PcG proteins form 
multiprotein repressive complexes, called polycomb repres-
sive complexes (PRCs). As repressors of transcription, 
PRCs silence specific genes by altering chromatin modifi-
cation. Here we review the biological functions and the 
molecular mechanisms of PcG proteins in oncogenesis. We 
also consider the potential role of PcG proteins in the diag-
nosis and treatment of cancer. 
1  What are polycomb group proteins? 
PcG proteins were first described in the fruit fly as re-
pressors of hox genes, based on mutant phenotypes involv-
ing posterior transformation of body segments. PcGs act by 
maintaining chromatin in a transcriptionally inactive or 
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“OFF” state [1]. PcG proteins work to regulate chromatin 
dynamics and gene expression cascades to preserve the de-
velopmental program of a cell. Since aberrations of the 
normal development program can result in cancer, the ab-
normal function of PcG proteins is associated with an in-
creased risk of cancer. At the molecular level, as shown in 
Table 1, PcG proteins are classified into two groups, poly-
comb repressive complex 1 (PRC1) and polycomb repres-
sive complex 2 (PRC2), based on their association with dis-
tinct classes of multimeric complexes [2].  
PRC2 establishes the histone code and PRC1 interprets 
this code. The mammalian PRC2 complex contains enhanc-
er of zeste homologue 2 (EZH2), embryonic ectoderm de-
velopment (EED), suppressor of zeste homologue 12 
(SUZ12) and retinoblastoma-binding protein 4 (RBBP4) or 
RBBP7 [3]. EZH2 contains a SET domain and is a histone 
methyltransferase (HMT). EZH2 attaches methyl groups to 
histone H3 at lysine 27, which is characteristic of PRCs that 
mediated inactive chromatin. Methylation of H3 at lysine 9 
is another repressive mark generated by PRCs. EED and 
SUZ12 do not possess HMT activity, but are required for 
HMT activity of EZH2. After PRC2 establishes the histone 
code (H3K27 tri-methylation and H3K9 tri-methylation), 
the repressive histone marks are recognized by PRC1. 
PRC1 contains chromobox homologue 2 (CBX2), either 
CBX4 or CBX8, polyhomeotic homologue 1 (PHC), PHC2 
or PH3, BMI1 and ring finger protein 1 (RING1) or ring 
finger protein 2 (RNF2). A working model of how PcG 
complexes modulate chromatin is as follows: Transcription 
factors and their associated machinery dictate loci destined 
for silencing, and PRC2 tags these target loci by methylat-
ing histone H3 at lysine 27. The H3K27me mark is recog-
nized and bound by the chromodomain of CBX2, CBX4 or 
CBX8 within PRC1, which mediates transcriptional silenc-
ing by binding methylated histones in the vicinity and by 
ubiquitinating histone H2A. Although in vitro assays have 
suggested that PRC complexes mediate silencing by physi-
cally blocking the binding of transcriptional machinery at 
promoters, PRCs are more likely to function by impeding 
RNA polymerase II (RNA Pol II) initiation or elongation 
[4,5]. In addition, the fact that EZH2 and CBX7 can physi-
cally associate with DNA methyltransferases (DNMTs) 
suggests that PcG proteins directly contribute to altered 
DNA methylation profiles [6]. Therefore, PcG proteins can 
integrate histone modifications, DNA methylation and 
chromatin remodeling in tumorigenesis to promote carcin-
ogenesis. 
2  What are the biological functions of PcG 
proteins? 
Upregulation of PcG proteins is commonly observed in hu-
man cancer, demonstrating the oncogenic potential of PcG 
proteins. For example, BMI1 and EZH2 are oncogenes. 
PRCs function reciprocally to regulate transcriptional 
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programs that affect apoptosis, cellular senescence and  
epithelial mesenchymal transitions. In addition, the co-    
operation between oncogenic virus and PcG proteins can 
transform host cells and lead to tumor formation.  
2.1  Apoptosis 
Apoptosis is the process of programmed cell death. Gener-
ally PcG proteins inhibit apoptosis of cancer cells. BMI1, 
the first PcG protein to be implicated in cancer, inhibits 
apoptosis of cancer cells by binding to the CDKN2A locus. 
The CDKN2A locus encodes two structurally distinct tumor 
suppressor genes, p16INK4A and p14ARF. p16INK4A is a cy-
clin-dependent kinase inhibitor that activates the reti-
noblastoma (RB) pathway; p14ARF facilitates apoptosis by 
inhibiting MDM2-mediated ubiquitination and degradation 
of p53. bmi1–/– mice have increased apoptosis in lymphoid 
tissues, a phenotype that is rescued by depleting p16INK4A 
and p14ARF or by over-expressing the apoptosis inhibitor 
BCL2 [7]. Loss-of-function analysis of BMI1 using RNA 
interference (RNAi) in both normal and malignant human 
cells showed that loss of BMI1 promoted cancer specific 
cell death, as well as an increased production of cleaved 
caspase-3 and the increased expression of proapoptotic gene 
Bim [8]. On the other hand, an S-adenosylhomocysteine 
hydrolase inhibitor, 3-deazaneplanocin A (DZNep), induces 
efficient apoptotic cell death in cancer cells but not in nor-
mal cells. This is because DZNep can effectively deplete 
cellular levels of PRC2 components EZH2, SUZ12 and 
EED, reduce tri-methylation of H3K27 and activate the ex-
pression of the apoptosis effector F-box-only protein 32 
(FBXO32) [9]. To summarize, loss of PcG-mediated re-
pression causes apoptosis; increased PcG-mediated activity 
contributes to the inhibition of apoptosis in cancer cells. 
2.2  Cellular senescence 
Cellular senescence is the phenomenon by which normal 
diploid cells lose the ability to divide (normally after about 
50 cell divisions in vitro). It is widely believed that cellular 
senescence evolved as a way of preventing the onset and 
spread of cancer. BMI1, co-operating with MYC, facilitates 
tumorigenesis by mediating escape from cellular senescence, 
which is a state of withdrawal from the cell cycle that pro-
vides a potent tumor suppressive mechanism in vivo [10]. 
As mentioned above, CDKN2A and CDKN2B loci encode 
three cellular senescence inducers, p14ARF, p15 INK4B and 
p16INK4A. BMI1 represses both CDKN2A and CDKN2B loci 
simultaneously by mediating the loading of CDC6 onto a 
cis-acting replication origin several thousand nucleotides 
upstream of the transcriptional start site. Recently, studies 
have shown that chromobox 7 (CBX7) within PRC1 binds 
to a long non-coding RNA, ANRIL, and both CBX7 and 
ANRIL are found at elevated levels in prostate cancer tis-
sues. In concert with H3K27me recognition, binding to 
RNA contributes to CBX7 function and disruption of either 
interaction impacts the ability of CBX7 to repress the 
CDKN2A-CDKN2B locus and to control senescence [11]. 
These observations provide the new insight that PcG pro-
teins play a crucial role in the cellular senescence process. 
2.3  Epithelial mesenchymal transition 
The epithelial mesenchymal transition (EMT) is a develop-
mental process in which epithelial cells lose their polarity 
and acquire the migratory properties of mesenchymal cells. 
A recent breakthrough has shown that EMT plays a very 
important role in promoting the metastasis of cancer and in 
generating cancer cells with some properties that are similar 
to those of stem-cells [12]. These findings provide a crucial 
link between the acquisition of metastatic traits and tumor 
initiating capability in cancer cells undergoing EMT. EZH2 
has a master regulatory function in controlling certain pro-
cesses, such as stem cell differentiation, cell proliferation, 
early embryogenesis and X chromosome inactivation [13]. 
Epithelial cells show very low levels of EZH2, but in-
creased levels of EZH2 have been observed in aggressive 
solid tumors, such as those observed in prostate, breast and 
bladder cancer. Repression of E-cadherin is a molecular 
marker of EMT. Studies have demonstrated that EZH2 and 
Suz12 mediate transcriptional silencing of the tumor sup-
pressor gene E-cadherin by trimethylation of histone H3 
lysine 27 [14,15], which promotes the metastasis of cancer. 
These observations provide a functional link between the 
dysregulation of PRC2 and the repression of E-cadherin 
during cancer progression. Recent research suggests that 
PRC1 is also involved in the metastasis of cancer. 
Up-regulation of BMI1 induced EMT and enhanced the 
motility and invasiveness of human nasopharyngeal epithe-
lial cells, whereas silencing endogenous BMI1 expression 
reversed EMT and reduced motility. Furthermore, 
up-regulation of BMI1 led to the stabilization of Snail, a 
transcriptional repressor associated with EMT, via the 
binding of BMI1 to the pten loci [16]. In head and neck 
squamous cell carcinoma (HNSCC), Twist1 and BMI1 act 
together to repress the expression of both E-cadherin and 
p16INK4a, which are correlated with the worst prognosis of 
HNSCC [17]. Together, those studies imply that PRC-  
induced EMT and metastasis of cancer via chromatin re-
modeling leads to unfavorable clinical outcomes and that 
targeting PRCs may be useful for the development of ther-
apeutic treatments. 
2.4  Transformation of host cells  
The WHO International Agency for Research on Cancer 
estimated that in 2002, 17.8% of human cancers worldwide 
were caused by infection, with 11.9% being caused by one 
of seven different viruses [18]. Analyses of tumor viruses 
have been instrumental in understanding cancer biology. 
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Several studies have reported how oncogenic virus-encoded 
proteins drive tumorigenesis via the deregulation of PcG 
proteins. The malignant phenotype of human papilloma 
virus (HPV)-positive cancer cells is maintained by the 
activity of viral E6 and E7 genes. EZH2 is an E7 target gene 
that is important in the proliferation of HPV-positive cancer 
cells, and contributes to their apoptotic resistance [19]. 
Epstein–Barr virus (EBV) is another tumor virus, which is 
associated with the development of several lymphoid and 
epithelial malignancies. Latent membrane protein 1 (LMP1) 
is the principal oncoprotein encoded by EBV. LMP1 
mediates the disruption of several important cell signaling 
pathways, including the AP-1, NF-kappaβ, STAT3 and 
EGFR pathways [20]. In Hodgkin lymphoma cells, BMI1 is 
up-regulated by LMP1, and this up-regulation is mediated 
by NF-kappaβ signaling. High levels of BMI1 contribute to 
LMP1-induced oncogenesis in Hodgkin lymphoma [21]. On 
the other hand, numerous tumor suppressor genes have also 
been identified as the cellular targets of tumor-causing 
viruses. Adenoviruses produce a protein called E1B-55k, 
which binds to p53, inhibiting its transcription-promoting 
activity and directing its degradation by the proteasome. For 
many years, this was believed to be the central adenovirus 
mechanism of carcinogenesis. Recently, it has been 
observed that infection with an adenoviral mutant that lacks 
E1B-55k results in high levels of p53, as expected, but the 
target genes of p53 are still deactivated. Furthermore, 
researchers have identified another virus-encoded gene, 
E4-ORF3, as a second repressor of p53. Crucially E4-ORF3 
selectively silences the activation of p53 target genes by 
mediating the tri-methylation of histone H3 at lysine 9 at the 
promoters of the target genes. E4-ORF3 does this through 
its effect on members of the cellular methylase enzyme 
family, SUV39 [22]. Although SUV39 is not a PcG protein, 
it is very similar to EZH2 because SUV39 has a SET 
domain. We propose that tumor viruses can inactivate tumor 
suppressor genes, not only by cooperating with PcG 
proteins, but also by increasing the expression of PcG 
proteins.  
3  How are PcG proteins recruited to target 
genes during oncogenesis? 
An increasingly large amount of work has established a 
functional link between PRCs and tumorigenesis. However, 
the mechanisms by which PcG proteins bind to target genes 
are still unclear. Analysis of the structure of PcG proteins 
has revealed that they do not have the ability to bind to spe-
cific DNA motifs (as DNMTs do) [23]. In Drosophila mel-
anogaster, one transcriptional factor, encoded by Yy1, has 
been shown to co-occupy most PREs along with PRC1 and 
PRC2 components. More interestingly, some PcG proteins 
contain an RNA binding motif [24]. These observations 
suggest that many different mammalian transcription factors 
or RNAs are required to recruit PcG proteins to polycomb 
repressive elements (PREs). In addition to this, recent stud-
ies demonstrate that JARID2 (an ARID-domain-containing 
protein) regulates binding of PRC2 to target genes in ES 
cells [25]. 
3.1  Cell fate transcription factors (CFTFs) 
CFTFs are transcription factors that function to regulate cell 
fate decisions during embryogenesis or adult cell differenti-
ation. CFTFs include Hox, Sox, OCT, Fox, Pax and Gata 
transcriptional factors. There is also strong evidence that at 
least 30 CFTFs, when altered, can contribute to cancer in a 
tissue-specific manner. CFTFs are strong candidates for the 
regulation of PcG protein recruitment to and dissociation 
from target genes [23]. OCT4 is normally expressed in plu-
ripotent cells of the early embryo and in ES cells, and it is 
also required for producing iPS cells. A potential oncogenic 
activity of OCT4 was discovered when it was found to be 
highly expressed in human germ cell tumors and was shown 
to be required for the continued growth of the aforemen-
tioned tumors. In addition, the ectopic expression of OCT4 
blocks progenitor cell differentiation and causes dysplasia 
in epithelial tissues [26]. Importantly, OCT4 can occupy 
several hundred PcG protein target genes and it is thought to 
contribute to the sustained recruitment of PcG proteins to the 
promoters of target genes [27]. Some other CFTFs can form 
fusion proteins, such as the promyelocytic leukemia 
(PML)—RAR fusion protein, which aberrantly recruits PcG 
proteins to target genes during cancer development [28].   
3.2  Long non-coding RNAs (long ncRNAs) 
In addition to well-characterized protein coding mRNAs 
and microRNAs, long ncRNAs are also emerging as im-
portant regulatory molecules in tumor-suppressor and on-
cogenic pathways. Long ncRNAs are over 200 nucleotides 
in length, and are often transcribed from gene loci that are 
interspersed with and overlap coding genes. Recent studies 
have found that long ncRNAs regulate key cancer pathways 
at transcriptional, post-transcriptional and epigenetic levels 
by serving as a regulator of PRC2. Long ncRNAs help to 
recruit PcG proteins to the promoters of target genes [29]. 
HOX transcript antisense RNA (HOTAIR), a long ncRNA 
located among the hox loci, becomes systematically dysreg-
ulated during breast cancer progression. The expression of 
HOTAIR is higher in metastatic breast cancer than in pri-
mary breast epithelial cells. Enforced expression of 
HOTAIR in epithelial cancer cells induces genome-wide 
re-targeting of PRC2 onto numerous tumor suppressor 
genes and leads to alteration of the tri-methylation of his-
tone H3 at lysine 27 of target gene promoters. Tumor sup-
pressors, such as JAM2, PCDH10 and PCDHB5, are tran-
scriptionally repressed after HOTAIR expression and 
de-repressed after concomitant PRC2 depletion [30]. The 
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long ncRNA, ANRIL, (described above) interacts with 
CBX7, a component of PRC1, to epigenetically silence 
p14ARF, p15INK4B and p16INK4A [11]. 
4  Diagnostic and therapeutic implications of 
PcG proteins 
Numerous studies have discovered a functional link be-
tween PcG proteins and carcinogenesis, which means that 
PcG proteins can serve as useful diagnostic markers, or as 
prognostic markers for predicting clinical behavior. The 
expression of BMI1 and EZH2 indicates high cancer cell 
proliferation rates and poor outcome for the patient. BMI1 
and EZH2 have been identified as potential diagnostic and 
prognostic markers for several cancer types. Targeting PcG 
proteins is a valid therapeutic strategy because decreased 
levels of BMI1 and EZH2 induce cancer cell specific apop-
tosis and inhibit chemoresistance in tumors undergoing PcG 
protein-induced EMT [8,9]. MicroRNAs (miRNAs) are 
short ribonucleic acid (RNA) molecules; they are 
post-transcriptional regulators that bind to complementary 
sequences on target mRNAs, usually resulting in transla-
tional repression and gene silencing. Recent studies have 
revealed that a subset of miRNAs, including miR26a and 
miR101, control the expression of polycomb group genes. 
In vitro and in vivo experiments indicate that therapeutic 
delivery of these miRNAs inhibits cancer cell proliferation 
and induces tumor-specific apoptosis [31,32]. Dietary ome-
ga-3 polyunsaturated fatty acids suppress the expression of 
EZH2 in breast cancer cells [33]. Similarly to PcG proteins, 
CFTFs and long ncRNAs could also be possible diagnostic 
and prognostic markers, or targets for cancer treatment. 
There have been multiple investigations into using the DNA 
methylation status of HOXA9 genes as biomarkers. In 
breast cancer, a two-gene test using qPCR to determine the 
ratio of HOXB13 expression to IL17RB expression that 
enables the prediction of tumor recurrence in patients with 
ER-positive tumors taking tamoxifen has already been de-
veloped. Some Hox tumor suppressor genes are epigenet-
ically silenced, and, therefore, the use of HDAC or DNMT 
inhibitors together with conventional chemotherapies may 
make the tumors more susceptible to drugs and result in 
fewer metastases [34]. In conclusion, further research on 
PcG proteins and their co-factors will generate new possi-
bilities for using PcG proteins as diagnostic markers and as 
targets for new intervention strategies. 
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